Sm04554

[KO1]

PHase I was just safety, they're unlikely to release efficacy data....if they even gave it enough time to work.

[paulneedshair]

looks good

[macbeth81]

PHase I was just safety, they're unlikely to release efficacy data....if they even gave it enough time to work.

Anyone notice how they used a higher dosage during Phase I safety trials? Phase I used 0.05%, 0.15%, and 0.45%, while Phase II is using only 0.15% and 0.25%. Would there be safety issues regarding manipulating WNT pathways?

The only other explanation is that they found 0.45% unnecessary and are narrowing down to the most efficient dosage.

Doesn't this work similar to Histogen?

[LMS]

Doesn't this work similar to Histogen?

Kind of but not really. Histogen is growth factors which activate numerous pathways of which the WNT pathways is one of them. This drug merely activates the WNT pathway if I am correct. So different MoAs above all.

[KO1]

I think they just wanted to overdose just to check the tolerable range. But there are definitely safety issues with Wnt - it is an important signal in cancer growth.

[hgs1989]

regarding cancer, from my understanding is that wnt cause proliferation of cells and over expressed in caner cells which provide cancer the ability to spread and proliferate fast. in addition wnt is also required for certain type of carcinogenesis. the over proliferation of cells can lead to mutation that causes cancer. this is why wnt is effective in hair regeneration because it causes cells differentiation and proliferation.

[The Alchemist]

Anyone notice how they used a higher dosage during Phase I safety trials? Phase I used 0.05%, 0.15%, and 0.45%, while Phase II is using only 0.15% and 0.25%. Would there be safety issues regarding manipulating WNT pathways?

The only other explanation is that they found 0.45% unnecessary and are narrowing down to the most efficient dosage.

Doesn't this work similar to Histogen?

Phase I trials are done to assess the safety of the treatment. They are done at doses higher than what would be administered in the final commercial product. You have to be able to define the toxicity, or lack there of, at the dosage levels intended to be used in the general public. The only way to do this is by exceeding the therapeutic dose and seeing if there is toxicity. If the safety profile is clean at a higher dose, they can proceed with future trials with little concern that lower doses would be toxic.

[Shinobi]

Im wondering by wich mecanism this molecule works. What is the target ? We already have study on hair promoting effect for VPA as gsk3 inhibitor which then increase b catenin in nucleus (proteasome inhibitors also upregulate beta-catenin levels). We also have other good candidate for such purpose like 6-bio wich is a potent, reversible and ATP-competitive gsk3a/β inhibitor. This molecule is used in cell culture to maintain the properties of DP cells intact.

Such molecules are by defintion anti cells proliferation activity so scientific use growth factor such as FGF2 in the media.

There is a lot of question awaiting for an answer for this molecule. I would like more information about it

[KO1]

Im wondering by wich mecanism this molecule works. What is the target ? We already have study on hair promoting effect for VPA as gsk3 inhibitor which then increase b catenin in nucleus (proteasome inhibitors also upregulate beta-catenin levels). We also have other good candidate for such purpose like 6-bio wich is a potent, reversible and ATP-competitive gsk3a/β inhibitor. This molecule is used in cell culture to maintain the properties of DP cells intact.

They have not released the mechanism by which it works, it might be a GSK-3b modulator, in which case I expect it to be more potent than VPA or 6BIO. This is a Pfizer molecule which the firm found in their chemical library and have the rights to.

Such molecules are by defintion anti cells proliferation activity so scientific use growth factor such as FGF2 in the media.

This is not correct, it will promote cell proliferation.

[Swooping]

I hope we can get some more information about this trial, hopefully we will get updated through the 2nd trial so we will know the effectiveness. Somebody should sign up from the forum that would be awesome. I hope it will be more selective and better acting than something like VPA, that would be awesome.

[Boldy]

They have not released the mechanism by which it works, it might be a GSK-3b modulator, in which case I expect it to be more potent than VPA or 6BIO. This is a Pfizer molecule which the firm found in their chemical library and have the rights to.



This is not correct, it will promote cell proliferation.

normal gsk3b inhibitors slowdown fibroblast proliferation (in vpa and bio studies)

[KO1]

But don't they promote proliferation of TA cells?

[KO1]

I hope we can get some more information about this trial, hopefully we will get updated through the 2nd trial so we will know the effectiveness. Somebody should sign up from the forum that would be awesome. I hope it will be more selective and better acting than something like VPA, that would be awesome.

Yep, we need to get the word out....all the guys who don't take any meds for hair loss can sign up for this....maybe Spencer Kobren can promote this?

[deuce]

Sucks because a lot of us will be NW5-6 by the time this comes out.Wish I was born 5 years earlier.

[Boldy]

Yep, we need to get the word out....all the guys who don't take any meds for hair loss can sign up for this....maybe Spencer Kobren can promote this?

im not sure, i will read the latest study tomorrow , a vary interesting one, it is at least partly responsible for differentiation: https://www.dropbox.com/s/0716ky9q3r...Genes.pdf?dl=0

but it doesn't matter, the vpa/bio studies show slowed down fibroblast proliferation in vitro (where you want to expand as much as possible), vivo is different story anyway